Puma Biotechnology reported second quarter 2026 financial results with net product revenue of $53.6 million, up from $49.2 million in the prior year period. GAAP net income was $8.2 million, or $0.16 per diluted share, compared to $5.9 million, or $0.12 per diluted share, in Q2 2025. The company raised its full-year 2026 revenue guidance to $224–$231 million and net income guidance to $17–$20 million, citing increased demand for NERLYNX. Puma also announced the final payment of principal, interest, and exit fees under its 2021 Note Purchase Agreement on May 4, 2026, reducing outstanding debt to zero. As of June 30, 2026, the company held $93.9 million in cash, cash equivalents, and marketable securities. Puma Biotechnology is a biopharmaceutical company focused on the development and commercialization of innovative products for cancer care.